ABSTRACT -2'-Deoxy-2'-methylidenecytidine (DMDC) is a potential anticancer deoxycytidine analog of cytosine arabinoside. Using monkeys, we conducted a 4-week toxicity study with toxicokinetics of DMDC at 1, 3, and 10 mg/kg/day and a dose-regimen study of three different schedules of once-daily administration (5 mg/kg/day) for 1 week every 2 weeks, 2 weeks every 4 weeks, and 3 weeks every 4 weeks. Deaths, myelosuppression, intestinal toxicity, and swelling of palm and sole skin were observed by oral DMDC treatment at 10 mg/kg/day in 4-week repeated toxicity study; however, no skin disorders have been reported in humans. No notable changes were observed at 1 and 3 mg/kg/day. The curves of dose vs. AUC and the AUC at MTD in monkey are similar to those in humans. In the dose-regimen study, all the toxicities were reversible but more severe toxicity was observed with the longer administration periods. One-week interruption showed sufficient recovery of decreased WBC in dosing regimens of 1-week-on/1-week-off and 2-weeks-on/2-weeks-off. A 2-week recovery period was almost sufficient for the recovery of decreased RBC, HCT, and skin disorders in the 2-weeks-on/2-weeks-off regimen. Therefore, once-daily for 2 weeks every 4 weeks was concluded to be the optimal dose regimen. In summary, myelosuppression, intestinal toxicity, and skin disorders were observed in DMDC treatment in monkeys, the relationship between AUC and toxicity in monkeys was close to that in humans, and in preclinical studies, it is advantageous to investigate optimal dose regimens using the appropriate species.
INTRODUCTION
DMDC was designed and synthesized as a novel deoxycytidine analog and is structurally related to cytosine arabinoside (Ara-C) and gemcitabine (Takenuki et al., 1988) . DMDC and gemcitabine are metabolized to mono-, di-, and triphosphate forms by deoxycytidine kinase after incorporation into cells. DMDC triphosphate inhibits DNA synthesis (Takenuki et al., 1988; Ono et al., 1996) and DMDC diphosphate inhibits ribonucleotide reductase as a mechanismbased inhibitor (Baker et al., 1991) . DMDC showed broad anticancer activities in murine leukemia and solid tumors and in human xenograft models such as lung cancer, melanoma, colon cancer, and pancreas cancers (Yamagami et al., 1991; Miwa et al., 1998) . DMDC is reported to be resistant against cytidine (Cyd) deaminase from mouse kidney which metabolizes DMDC to the inactive form 2'-deoxy-2'-methylidineuridine (DMDU) although ara-C was highly deaminated by this enzyme (Takenuki et al., 1988) . In addition, DMDC was highly effective in tumors with high levels of Cyd deaminase. In contrast, gemcitabine appeared to be less effective in tumors with high levels of Cyd deaminase .
Several phase I trials of DMDC have been performed with various dose regimens to find the optimal dose and administration schedule because DMDC is a highly schedule-dependent anticancer drug similar to ara-C (Yamagami et al., 1991) . In the first clinical trial, neither once a week (200 to 450 mg/m 2 ) nor daily for 5 days (30 or 40 mg/m 2 ) intravenous administration revealed tumor suppression (Gemma et al., 1996) . Various dose regimens of oral administration such as oncedaily for 1 week every 3 weeks, once-daily for 10 days every 4 weeks, and once-daily for 2 weeks every 4 weeks have been evaluated in Phase I trials (van der Gaast et al., 1998a and 1998b; Masuda et al., 2000) . The dose-limiting toxicities of DMDC observed in these studies were grade 3 leucopenia, neutropenia, and thrombocytopenia. No tumor regression was reported as a result of DMDC treatment but long-lasting stability of disease was noted in 5 patients (van der Gaast et al., 1998a) .
Before starting the clinical trials of oral administration of DMDC, we performed a 4-week toxicity study and a dose-regimen study in monkeys, considered to be the appropriate species for evaluating the safety of DMDC. We used toxic endpoints such as hematological toxicity, intestinal toxicity, and skin disorder and AUC of DMDC in monkeys for the selection of the first dose in the clinical trials of oral DMDC (Horii, 1998; Masuda et al., 2000) . In the present studies, we describe the toxicity of DMDC in monkeys and the effects of dose regimen on the safety of DMDC and we show that investigation of dose regimen is advantageous in finding the optimal tolerable therapy in clinical trials for schedule-dependent anticancer drugs.
MATERIALS AND METHODS

Chemicals
DMDC and DMDU were obtained from Yamasa Co. (Choshi, Japan). The reagents used for the measurement of plasma concentration were of analytical grade.
Animals
All animal experiments were carried out in accordance with the Guide to the Care and Use of Experimental Animals of Nippon Roche Research Center. All animals were housed in individual cages and maintained in controlled conditions of room temperature (25 ± 2°C), relative humidity (55 ± 15%) and light cycle (12 hr/day). Male and female cynomolgus monkeys (body weight: male, 3.5-5.4 kg; female, 2.3-4.3 kg) were purchased from Shin Nippon Biomedical Laboratories (SNBL, Kagoshima, Japan). Monkeys received 100 g/day/body of Purina primate chow (Tokyo, Japan) and tap water ad libitum. After hematological and blood chemistry work-ups, monkeys determined to be in a normal condition were randomly allocated for treatment.
Toxicity testing
The test compound was dissolved in 5% gum arabic and administered orally by nasogastric tube to monkeys. DMDC was administered daily at doses of 1, 3, and 10 mg/kg/day for 4 weeks in male and female monkeys (n=4 per group). Mortality and clinical signs were recorded daily. Body weight was measured twice a week and food consumption was measured daily. After 4 weeks, 3 animals from each group were killed humanely and autopsies were performed. One monkey from each group was observed for recovery for 4 weeks and autopsies were then performed. For the dose-regimen study in monkeys, DMDC was administered orally at 5 mg/kg/day following three different schedules: (A) once daily for 1 week every 2 weeks (1-week-on/1-week-off), (B) once daily for 2 weeks every 4 weeks (2-weeks-on/2-weeks-off), or (C) once daily for 3 weeks every 4 weeks (3-weeks-on/1-week-off). The regimens were continued for 4 cycles in male monkeys (n=3 per group).
Hematological examination
Blood was collected before the administration (Pre), on Days 10 (10 mg/kg only), 14, and 28 in monkeys in 4-week toxicity study. In the dose-regimen study, blood was collected at Pre in the first cycle, at the end of the administration period, and at the end of the recovery period in each treatment cycle. Blood was collected on the following days for the various regimens: Pre, Days 7, 14, 21, 28, 35, 42, 49 , and 56 (once daily for 1 week every 2 weeks), Pre, Days 14, 28, 42, 56, 70, 84 , and 98 (once daily for 2 weeks every 4 weeks), Pre, Days 21, 28, 49, 56, 77, 84 , and 105 (once daily for 3 weeks every 4 weeks), and Pre, Days 21, 28, 49, 56, 77, 91, and 105 (control) . Red blood cell (RBC) count, white blood cell (WBC) count, hematocrit (HCT), hemoglobin (Hb) concentration, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelet (PLT) count, and differential white Vol. 32 No. 4 blood cell (%) were determined using a Technicon autoanalyzer H-1 (Tokyo, Japan). Bone marrow cell (BMC) counts were determined using Sysmex F-300 (Hyogo, Japan).
Histopathological examination
After the 4-week administration period for the toxicity study, animals were necropsied and organs were weighed and fixed in 15% buffered formalin (pH 6.8). Fixed organs (spleen, bone marrow, thymus, lymph node, liver, kidney, heart, lung, brain, duodenum, jejunum, ileum, colon, rectum, skin, etc.) were embedded in paraffin, sectioned, and stained with hematoxylin and eosin. Histopathological examinations were performed microscopically.
Toxicokinetics
Blood was collected at 0.5, 1, 2, 4, 8, and 24 hr after administration on Days 0, 10 and 27 for the 4-week toxicity study. In the dose-regimen study, blood was collected at 0.5, 1, 2, 4, 8, and 24 hr after administration on the first day of the first and second treatment cycles. Heparine was used as an anticoagulant. Plasma was stored at −70°C until analysis. Area under the concentration-time curve from time 0 to last measured time point (AUC 0-t ) was calculated by linear trapezoidal rule using WinNonline software ver. 2.1 (Pharsight, CA, USA). Peak plasma concentration (C max ) and time to C max values (T max ) were read directly from the plasma concentration profile.
Measurement of plasma concentration
High-performance liquid chromatography (HPLC) with UV detection and column-switching was used for the quantification of DMDC and DMDU concentrations in plasma. 100 μl aliquots of plasma were precipitated with 50 μl of 2 M perchloric acid and samples were vortex-mixed. 50 μl of 2 M potassium hydroxide was then added and the samples were vortex-mixed. After centrifugation, 100 μl of the supernatant was transferred to HPLC vials which contained 100 μl of 0.1 M phosphate buffer (pH 3.5). After vortex-mixing, 100 μl aliquots were injected into the HPLC system. Capcell pack C18 (UG-120, 4.6 mm I.D. × 150 mm, 5 μm, Shiseido, Tokyo, Japan) was used as the precolumn and an L-column (C18, 4.6 mm I.D. × 250 mm, 5 μm, Kagakuhin Kensakyokai, Tokyo, Japan) was used as the analytical column. For DMDC, the mobile phase A was 50 mM phosphate buffer (pH 2.2)/methanol (98/2, v/v) for the precolumn and mobile phase B was 100 mM phosphate buffer (pH 3.8)/methanol (99/1, v/v) for the analytical column. For DMDU, mobile phase C was 50 mM phosphate buffer (pH 2.2)/methanol (95/5, v/v) for the precolumn and mobile phase D was 100 mM phosphate buffer (pH 4.0)/methanol (95/5, v/v) for the analytical column. The flow rate was 0.8 ml/min for mobile phases A and C and 1.0 ml/min for mobile phases B and D: analytes were quantified by UV at 275 nm. Each sample was injected into a precolumn which was pumped with mobile phase A (for DMDC) or C (for DMDU) for 3 min. After 3 min, the valve was switched allowing the precolumn to align with the analytical column and mobile phase A or C was pumped through both columns. At 5 min, the valve was switched allowing mobile phase A or C to be backflashed through the precolumn to waste and mobile phase B (for DMDC) or D (for DMDU) to be pumped through the analytical column to the detector. At 15 min, mobile phase A or C was flushed through the precolumn to waste, and mobile phase B or D was pumped through the analytical column. The quantification limit for both DMDC and DMDU was 0.02 μg/ml.
RESULTS
Four-week toxicity study in monkeys 1. Mortality and clinical signs
Mortality and clinical signs for the 4-week toxicity study in monkeys are summarized in Table 1 . No test compound-related deaths or clinical signs were observed at 1 mg/kg/day in either males or females or at 3 mg/kg/day in males. No deaths were observed at 3 mg/kg/day in females but in 1 female on Day 28, exfoliation of epidermis at palm and sole was observed. At 10 mg/kg/day, a decrease in food consumption was recorded from Day 5 and Day 3 in males and females, respectively and 3 males and 3 females died between Day 10 and 17. Diarrhea was observed from Day 6 and decreased motor activity was observed from Day 9 in the animals that died. The male and female at 10 mg/ kg/day that survived for 4 weeks both showed exfoliation of epidermis at palm and sole on Day 27.
Hematological observations
Hematological changes on Days 10, 14, and 28 during the 4-week administration period are shown in Table 2 . At 10 mg/kg/day, a decrease in WBC was observed on Day 10 in males and on Days 10, 14, and 28 in females. Slight decreases in RBC, HCT, and Hb were observed on Days 14 and 28 in males. Severe decrease in BMC was observed in dead animals at 10 mg/kg/day. No bone marrow samples were collected from 1 male and 2 females of dead monkeys due to myelosuppression. No notable changes were observed in the monkeys administered 1 and 3 mg/kg/day.
Histopathological findings
Histopathological findings after the 4-week administration period (Day 28) and for dead animals at 10 mg/kg/day are shown in Table 3 . Moderate atrophic changes in lymph-node, spleen, and bone marrow, moderate changes in intestines, and ulcer, swelling or inflammatory changes in the footpad skin (palm and sole) were observed at 10 mg/kg/day in both male and female monkeys. Hematopoietic and intestinal changes at 10 mg/kg/day were more severe in the dead animals compared with the survived animals. Slight atrophic changes in lymph-node and slight swelling and inflammatory changes of footpad skin (palm and sole) were observed at 3 mg/kg/day in both male and female monkeys. No notable changes were observed at 1 mg/kg/ day in either male or female monkeys.
Toxicokinetics
Cmax and AUC values of DMDC and DMDU following oral administration on Days 0, 10, and 27 are shown in Table 4 . Cmax and AUC values for DMDC increased dose-dependently from 1 to 10 mg/kg/day on Day 0. Similar Cmax and AUC values were observed during the administration period at 1 and 3 mg/kg/day on Days 0, 10 and 27: no gender difference was observed. However, Cmax and AUC values at 10 mg/ kg/day decreased on Days 10 and 27 compared with Day 0. Cmax and AUC of DMDU were almost the same as for DMDC during the administration period. The Cmax and AUC values for DMDU increased dosedependently with 1 and 3 mg/kg/day but less than dose-proportional at 10 mg/kg/day.
Dose-regimen study in monkeys 1. Mortality and clinical signs
Mortality and clinical signs in the dose-regimen study are summarized in Table 5 . In the regimen of once-daily for 1 week every 2 weeks, no deaths and no Table 1 . Mortality and clinical signs observed in 4-week toxicity study of DMDC in monkeys. clinical signs were observed. In the regimen of oncedaily for 2 weeks every 4 weeks, no deaths were observed. Body weight gain decreased during the third to eighth week and then it showed a plateau until the end of the study. Decreased food consumption was recorded in the latter part of the administration period but was recovered during the recovery period. This pattern was repeated in the next cycle but no changes were Values are mean ± SD, n: number of animals, nd: not determined, * For male: n=4 (Pre), n=2 (Day 10) and n=1 (Days 14 and 28); for female: n=4 (Pre), n=3 (Day 10), n=2 (Day 14) and n=1 (Day 28). **: Data from dead animals: n=2 (male) and n=1 (female). Table 3 . Histopathological findings of a 4-week toxicity study of DMDC in monkeys (necropsied on Day 28). (2) 6.54 ± 7.65 (5) 3.76 ± 2.02 (8) 0.26 (2) 0.54 ± 0.37 (5) 0.63 ± 0.33 (8)
Overall
Values are mean ± SD. Number of animals is expressed in parenthesis.
observed beyond the second cycle. Swelling of the palm and sole skin was observed near the end of the 2-week administration regimen and continued for approximately 2 weeks and then recovered. This pattern, observed from Day 12 to 26, Day 39 to 53, Day 68 to 74 and Day 94 to 109 in 2 or 3 animals, was repeated until the end of the study (Fig. 1) . A decrease in motor activity was observed from Day 20 to 23, Day 47 to 51
and Day 75 to 79 in 1 animal. In the regimen of oncedaily for 3 weeks every 4 weeks, one animal died on Day 88 during the recovery period of the third cycle. Body weight gain decreased during the second to eighth week and then it showed a plateau until the end of the study. A decrease in food consumption was recorded in the latter part of the administration period but recovered during the recovery period. This pattern Table 5 . Mortality and clinical signs in a dose-regimen study of DMDC in male monkeys. 
Hematological changes
Changes in WBC, RBC, and HCT during the study period are illustrated in Fig. 2 . In the once-daily 1-week-on/1-week-off regimen, WBC decreased after the 1-week administration (Day 7) but recovered to the initial level by the end of the 1-week recovery period (Day 14) . This pattern continued for the following 2 cycles. In the once-daily 2-weeks-on/2-weeks-off regimen, WBC decreased on Day 14 after the 2-week administration period and increased to the initial level on Day 28 after the recovery period. This pattern continued following 2 cycles. In the once-daily 3-weekson/1-week-off regimen, no change in WBC was observed after the 3-week administration period in the first cycle (Day 21) or the second cycle (Day 49). However, WBC increased after the week of recovery of the second cycle (Day 56) and decreased by the end of the following 3-week administration period (Day 77) and then increased after the week of recovery for the third cycle (Day 84). This pattern was also observed in the fourth cycle.
In the once-daily regimen of 1-week-on/1-weekoff, RBC and HCT had decreased slightly after the 1-week administration period (Day 7), and then RBC and HCT plateaued for the following 3 cycles. In the oncedaily regimen of 2-weeks-on/2-weeks-off, RBC and HCT decreased slightly after the 2-week administra- Fig. 2 . Changes in WBC, RBC, and HCT during the dose-regimen study in monkeys with control ( ), once-daily for 1 week every 2 weeks ( ), once daily for 2 weeks every 4 weeks ( ), and once-daily for 3 weeks every 4 weeks ().
Vol. 32 No. 4 tion period (Day 14) and increased very slightly after 2-week recovery period (Day 28). This pattern continued for the following 2 cycles. In the once-daily, 3-weeks-on/1-week-off regimen, RBC and H CT decreased gradually by the end of the 3-week administration period in the second cycle (Day 49) and then increased gradually by the end of the 3-week administration period in the third cycle (Day 77). No changes were observed at the end of forth cycle (Day 84 or 105).
Toxicokinetics
Cmax and AUC values for DMDC following oral administration at 5 mg/kg/day in the dose-regimen study in monkeys are shown in Table 6 . Similar mean AUCs for DMDC at 5 mg/kg/day were observed in all three regimens on the first day of both the first and second cycles of treatment.
The relationship between toxicity and AUC in monkey and human
The relationship of dose (mg/m 2 ), AUC, and toxicity in monkey and humans is shown in Fig. 3. No observed adverse effect level (NOAEL), lowest observed adverse effect level (LOAEL), and lethal dose of DMDC in monkeys were calculated at 12, 36, and 120 mg/m 2 , respectively, by the conversion factor 12 for 1, 3, and 10 mg/kg/day from the results of the 4-week toxicity study. The maximum tolerable dose (MTD) in monkeys was calculated to be 60 mg/m 2 Table 6 . Cmax and AUC of DMDC in dose-regimen study in monkeys. from the results of the once-daily regimen of 2 weeks every 4 weeks at 5 mg/kg/day. The mean value of AUCs from the first and second cycles of the regimen of 2 weeks every 4 weeks was used as the AUC at MTD in monkeys. The AUC at MTD in humans is reported to be 0.6033 and 1.42 μg*hr/ml at 18 mg/m 2 once daily for 14 days every 4 weeks and at 40 mg/m 2 once daily for 10 days every 4 weeks, respectively (Masuda et al., 2000; van der Gaast et al., 1998a) . The AUC at 30 mg/m 2 has been reported to be 1.10 μg*hr/ ml in a regimen of once-daily for 10 days every 4 weeks (van der Gaast et al., 1998a) . As shown in Fig.  3 , the steepness of the curve for dose (mg/m 2 ) vs. AUC in humans is similar to that in monkeys and the AUC at MTD in humans is close to that in monkeys.
DISCUSSION
Toxic effects from DMDC were observed in the hematological organs, intestinal tract, and skin of monkeys. Severe myelosuppression and intestinal toxicities were observed at the lethal dose of 10 mg/kg/day. Although hematological toxicity was not clearly observed in this 4-week toxicity study, the animals that died showed severe bone marrow and intestinal toxicities compared with the animals that survived at 10 mg/ kg/day, suggesting these toxicities to be the cause of death. The hematological toxicity of DMDC appeared more severe in WBC than in RBC and HCT both in the 4-week toxicity and dose-regimen studies. The adverse events observed in this study of ulcer, epidermal swelling, and inflammatory cell infiltration in the corium of the palm and sole have not been reported in humans. Skin disorders are considered species specific or an excessive response in monkeys. The dose-regimen study showed that all of the toxicities observed in monkeys were recoverable and thus manageable in clinic. It has been reported in several phase I studies that leucopenia, neutropenia and thrombocytopenia are the dose-limiting toxicities of DMDC in humans, in addition to mucositis, diarrhea, rash, and nausea (Masuda et al., 2000; van der Gaast et al., 1998a and 1998b; Pluzanska et al., 1998; Gemma et al., 1996) . In this study, the AUC of DMDC for the monkeys that died at 10 mg/kg/day were approximately twice as high as for the animals that survived (4.20-5.91 μg*hr/ml vs. 2.52 μg*hr/ml) on Day 0, suggesting individual difference of systemic exposure might be related to the toxic effects of DMDC.
DMDC is known as a schedule-dependent anticancer drug. Daily 5-day administration of DMDC was more effective than single administration in a murine tumor model even though the total dose was equivalent (Yamagami et al., 1991) . In clinical trials, twice daily administration was more toxic than once-daily administration (van der Gaast et al., 1998a and 1998b; Pluzanska et al., 1998) . Our monkey studies also demonstrated that toxicity of DMDC was more severe with a longer period of daily administration, but possibly necessary to achieve desired efficacy. Thus, a dosing schedule to optimize efficacy with manageable toxicity in DMDC chemotherapy is needed. To manage the dose-limiting toxicity myelosuppression, we investigated the recovery of WBC, RBC, and HCT in several dose regimens of varying administration and recovery periods.
We found that 1 week was sufficient for WBC recovery. A clear cycle of decrease and recovery were observed in both the once-daily regimens of 1-weekon/1-week-off and 2-weeks-on/2-weeks-off. Friberg et al. (2002) developed a semimechanistic pharmacokinetic-pharmacodynamic model to describe chemotherapy-induced myelosuppression. They demonstrated that the model predicted myelosuppression from administration of several anticancer drugs such as docetaxel, paclitaxel, etoposide, CPT-11, vinflunine, and DMDC using fixed system-related parameters and drug-related parameters. The model consisted of a compartment of proliferative cells, transit compartments with maturing cells, and a compartment of circulating blood cells. Furthermore, a feedback mechanism from the circulating cells was incorporated into the model as a rebound phenomenon. They used 123 hr (5.1 days) as the mean transit time. This is comparable to our results of approximately 1 week for recovery of WBC. In the regimen of once-daily for 3 weeks every 4 weeks, no change was observed in WBC. Because we measured WBC at the end of the 3-week administration period only, we did not monitor the early decrease and rebound increase within the 3-week administration period. We speculated that a decrease in WBC might have occurred within the first 2 weeks and the overshot rebound during the following week.
A 2-week recovery period seemed almost sufficient for the recovery of RBC and HCT because decreases and recovery cycles were observed in the 2-weeks-on/2-weeks-off regimen but not in the 1-weekon/1-week-off or the 3-weeks-on/1-week-off regimen. A 2-week recovery period also seemed almost sufficient for the recovery of skin disorder for the 2-weekson/2-weeks-off regimen but 1 week of recovery was insufficient for the 3-weeks-on/1-week-off regimen.
Our results show that more than 2 weeks of interruption of treatment is necessary for the recovery of RBC, HCT, and skin disorders in monkeys. For DMDC, once daily for 2 weeks every 4 weeks may be the optimal regimen because administration for 1 week shows diminished efficacy. Once-daily administration for 3 weeks may be possible but requires careful management of the toxicity. Miwa et al. (1998) reported that the efficacy of DMDC correlates well with tumor levels of Cyd deaminase in human cancer xenograft models. DMDC was highly effective in tumors with higher levels of Cyd deaminase, whereas lower levels yielded only slight activity. DMDC was highly resistant to Cyd deaminase, which deaminates the deoxycitidines (dCyds) to inactive molecules, whereas gemcitabine was susceptible to the enzyme. The Vmax/Km of Cyd deaminase for DMDC was 736 times lower than that for gemcitabine . dCyd, a natural substrate of both Cyd deaminase and dCyd kinase, suppressed the antiproliferative activity of DMDC. Because the Vmax/Km of dCyd kinase for DMDC was 8-fold lower than for dCyd, the activation of DMDC to DMDC monophosphate by dCyd kinase might be competitively inhibited by dCyd. Eda et al. (1998) speculated that Cyd deaminase reduces the concentration of dCyd and consequently increases the susceptibility of tumor cells and tumor tissues to DMDC. If this mechanism could be also applied to normal cells and tissues for toxicity of DMDC, Cyd deaminase activity in the toxicological target cells and production of DMDC phosphates may be important to elucidate the toxic response.
Plasma concentration of DMDU, an inactive metabolite of DMDC metabolized by Cyd deaminase, was similar to that of DMDC in monkeys. Cyd deaminase is widely distributed in various tissues with high levels in monkeys and is found more in liver and spleen than in other tissues in humans when 5'-deoxy-5-fluorocitidine is used as a substrate (Onodera et al., 2000) . Plasma concentration of DMDU was found to be similar to that of DMDC in humans (Brindley et al., 2000) , suggesting overall systemic activity of Cyd deaminase in humans might be similar to that in monkeys. Because the steepness of the curve for dose (mg/m 2 ) vs. AUC curve is similar for monkeys and humans and AUC at MTD in monkeys is close to that in humans, the monkey is a good animal for predicting the first dose of DMDC in clinical trials and may be a suitable animal for the investigation of dose regimen in preclinical studies. In addition, the vurve of dose (mg/m 2 ) vs. AUC in mice is different from that of both monkeys and humans and the relationship between toxicity and AUC in mice is also different from that in monkeys (data not shown). The AUCs of DMDC for LOAEL and lethal dose in mice are 5.48 and 49.5 μg*hr/ml, respectively, whereas in monkeys they are 0.95 and 3.22 μg*hr/ml, respectively. The species difference in toxicity from DMDC might be due to difference in Cyd deaminase activity, production of DMDC phosphates by dCyd kinase, and/or sensitivity to DMDC in normal cells. Cyd deaminase activity in mice is lower than that in monkeys and humans (Onodera et al., 2000) .
Ulcer, swelling of epidermis, and inflammatory cell infiltration in the corium in the palm and sole was observed from daily administration of DMDC in monkeys. However, no hand-foot syndrome has been reported in phase I trials of DMDC (Masuda et al., 2000; van der Gaast et al., 1998a and 1998b; Pluzanska et al., 1998) or in phase III trials in pancreatic cancer patients of the structurally-related anticancer drug gemcitabine (Abou-Alfa et al., 2006; Louvet et al., 2005) . It has been reported that hand-foot syndrome is one of the major side-effects of capecitabine, an oral prodrug of 5-fluorouracil, in humans. Grade 3 handfoot syndrome was observed in 16.2% and 18.1% of colorectal cancer patients in two phase III clinical studies of capecitabine (Hoff et al., 2001; Cutsem et al., 2001) and in 24% of breast cancer patients in a phase III clinical study (O'Shaughnessy et al., 2002) . However, it has been reported that the hand-foot syndrome caused by capecitabine is manageable with dose interruption and dose reduction without affecting antitumor efficacy (Gressett et al., 2006) . Therefore, if hand-foot syndrome is observed in humans from treatment with DMDC, it could be manageable as it is with capecitabine.
In conclusion, myelosuppression, intestinal toxicity and swelling of the palm and sole were observed by the treatment of DMDC at the lethal dose in monkeys. The relationship between the AUC of DMDC and toxicity in monkey was close to that of humans: However, no skin disorders have been reported in humans. A regimen of once-daily for 2 weeks every 4 weeks appears tolerable and a regimen of once-daily for 3 weeks every 4 weeks might be manageable in clinical trials. Investigation of dose regimen is advantageous in finding the optimal tolerable therapy in clinical trials for schedule-dependent anticancer drugs.
